These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9415889)

  • 41. Antibody directed enzyme prodrug therapy (ADEPT): clinical report.
    Bagshawe KD; Sharma SK; Springer CJ; Antoniw P; Boden JA; Rogers GT; Burke PJ; Melton RG; Sherwood RF
    Dis Markers; 1991; 9(3-4):233-8. PubMed ID: 1813213
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
    Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
    Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.
    Antoniw P; Springer CJ; Bagshawe KD; Searle F; Melton RG; Rogers GT; Burke PJ; Sherwood RF
    Br J Cancer; 1990 Dec; 62(6):909-14. PubMed ID: 2257218
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
    Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
    Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
    Günther M; Waxman DJ; Wagner E; Ogris M
    Cancer Gene Ther; 2006 Aug; 13(8):771-9. PubMed ID: 16543915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.
    Kokoris MS; Sabo P; Adman ET; Black ME
    Gene Ther; 1999 Aug; 6(8):1415-26. PubMed ID: 10467366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
    Schwartz PS; Chen CS; Waxman DJ
    Cancer Gene Ther; 2003 Aug; 10(8):571-82. PubMed ID: 12872138
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Production of Long-Acting CNGRC-CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment.
    Al-Mansoori L; Al Qahtani AD; Elsinga P; Goda SK
    Technol Cancer Res Treat; 2021; 20():15330338211057371. PubMed ID: 34802309
    [No Abstract]   [Full Text] [Related]  

  • 49. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.
    Frank S; Steffens S; Fischer U; Tlolko A; Rainov NG; Kramm CM
    Cancer Gene Ther; 2002 Feb; 9(2):178-88. PubMed ID: 11857036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.
    Sharma SK; Bagshawe KD; Springer CJ; Burke PJ; Rogers GT; Boden JA; Antoniw P; Melton RG; Sherwood RF
    Dis Markers; 1991; 9(3-4):225-31. PubMed ID: 1813212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
    J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suicide gene therapy using E. coli beta-galactosidase.
    Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).
    Misiura K; Szymanowicz D; Kuśnierczyk H; Wietrzyk J; Opolski A
    Acta Biochim Pol; 2002; 49(1):169-76. PubMed ID: 12136937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice.
    Gnant MF; Puhlmann M; Alexander HR; Bartlett DL
    Cancer Res; 1999 Jul; 59(14):3396-403. PubMed ID: 10416601
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
    Djeha AH; Hulme A; Dexter MT; Mountain A; Young LS; Searle PF; Kerr DJ; Wrighton CJ
    Cancer Gene Ther; 2000 May; 7(5):721-31. PubMed ID: 10830719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Image-guided enzyme/prodrug cancer therapy.
    Li C; Penet MF; Winnard P; Artemov D; Bhujwalla ZM
    Clin Cancer Res; 2008 Jan; 14(2):515-22. PubMed ID: 18223227
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
    Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
    Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine.
    Deckert PM; Bornmann WG; Ritter G; Williams C; Franke J; Keilholz U; Thiel E; Old LJ; Bertino JR; Welt S
    Int J Oncol; 2004 May; 24(5):1289-95. PubMed ID: 15067353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy.
    Thatcher NJ; Edwards RJ; Lemoine NR; Doehmer J; Davies DS
    Cancer Gene Ther; 2000 Apr; 7(4):521-5. PubMed ID: 10811468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.